Embla Medical hfOSSFF 92 Return-on-Tangible-Asset is 7.39% as of Mar. 2026, which is 36% below its 10-year median of 11.55. GuruFocus rates OSSFF with a GF Score™ of 92/100 and a GF Value™ of $5.29. The stock has 2 warning signs investors should review. Among 856 Medical Devices & Instruments companies, Embla Medical hf ranks better than 85.98% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Embla Medical hf's annualizedNet Income for the quarter that ended in Mar. 2026 was $57.8 Mil. Embla Medical hf's average total tangible assets for the quarter that ended in Mar. 2026 was $782.4 Mil. Therefore, Embla Medical hf's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 7.39%.
The historical rank and industry rank for Embla Medical hf's Return-on-Tangible-Asset or its related term are showing as below:
OSSFF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.13 Med: 11.55 Max: 23.34
Current: 11.06
During the past 13 years, Embla Medical hf's highest Return-on-Tangible-Asset was 23.34%. The lowest was 1.13%. And the median was 11.55%.
OSSFF's Return-on-Tangible-Asset is ranked better than 85.98% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.595
vs OSSFF: 11.06
Embla Medical hf (OTCPK:OSSFF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Embla Medical hf Return-on-Tangible-Asset Related Terms
Embla Medical hf Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSSFF vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Embla Medical hf's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 7.39% mean?
Embla Medical hf (OSSFF) has a Return-on-Tangible-Asset of 7.39% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Embla Medical hf and its competitors. This is 36% below median its historical median of 11.55. Over the past decade, Embla Medical hf's Return-on-Tangible-Asset has ranged from 1.13 to 23.34. According to the industry distribution chart, Embla Medical hf ranks #120 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 14%.
Is Embla Medical hf's Return-on-Tangible-Asset too high?
Embla Medical hf's current Return-on-Tangible-Asset of 7.39% is 36% below median its 10-year median of 11.55. Over the past 10 years, this metric has ranged from a low of 1.13 to a high of 23.34. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.60. Embla Medical hf's value of 7.39% is 1142% above this industry median. Based on the distribution chart, Embla Medical hf ranks #120 out of 856 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Embla Medical hf has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #120 out of 856 companies for Return-on-Tangible-Asset. This places Embla Medical hf in the top 14% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.60. Embla Medical hf's value of 7.39% is 1142% above this benchmark. Historically, Embla Medical hf's own Return-on-Tangible-Asset has ranged from 1.13 to 23.34 over the past decade. While the company's 10-year median is 11.55 vs. the industry median of 0.60, Embla Medical hf has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current Return-on-Tangible-Asset of 7.39% is 1142% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Embla Medical hf and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current Return-on-Tangible-Asset is 7.39%, which is 36% below median its own 10-year median of 11.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current Return-on-Tangible-Asset of 7.39%. The stock's GF Value™ is $5.29, compared to a current price of $4.15 — trading 21.6% below its estimated fair value. The current Return-on-Tangible-Asset is 7.39%, which is 36% below median its 10-year median of 11.55 and 1142% above the Medical Devices & Instruments industry median of 0.60. Embla Medical hf's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current Return-on-Tangible-Asset is 7.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OSSFF) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of $4.15 is trading 21.6% below its estimated GF Value™ of $5.29.
Key valuation signals for OSSFF:
Return-on-Tangible-Asset: 7.39% (36% below median its 10-year median of 11.55)
GF Value™: $5.29 vs. price of $4.15 (21.6% below fair value)
Industry Position: 1142% above the Medical Devices & Instruments median (#120 of 856)
No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score
Get the complete analysis for OSSFF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSSFF has been successfully added to your 
